ResearcherFred Hutch Cancer CenterActive in the last 2 years
Tara Elisabeth Seery
Matched on ORCID iD 0000-0003-2444-3896; OpenAlex author ID A5037755647. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 25
2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 2 papers
Papers 5
- Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate. First author DOI 10.1093/oncolo/oyae267↗
- Case report: PD-L1-targeted high-affinity natural killer cells and IL-15 superagonist N-803-based therapy extend overall survival of advanced metastatic pancre… Co-author DOI 10.3389/fonc.2025.1472714↗
- Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenoc… Co-author DOI 10.1200/jco.18.01295↗
- HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancrea… Co-author DOI 10.1200/jco.2017.74.9564↗
- Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomize… Co-author DOI 10.1001/jamaoncol.2016.5383↗
Closest collaborators
The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Patrick Soon‐Shiong · 2 shared papers, 2025 · strength 0.55
- Paper Case report: PD-L1-targeted high-affinity natural killer cells and IL-15 superagonist N-803-based therapy extend overal… DOI 10.3389/fonc.2025.1472714↗
- Paper Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate. DOI 10.1093/oncolo/oyae267↗
- Sandeep Bobby Reddy · 1 shared paper, 2025 · strength 0.28
- Katayoun Moini · 1 shared paper, 2025 · strength 0.27
- Himanshu N. Brahmbhatt · 1 shared paper, 2025 · strength 0.27
- Sunil R. Hingorani · 2 shared papers, 2018–2019 · strength 0.14
- Paper Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Pa… DOI 10.1200/jco.18.01295↗
- Paper HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Pat… DOI 10.1200/jco.2017.74.9564↗
- Philip A. Philip · 2 shared papers, 2017–2019 · strength 0.14
- Paper Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Pa… DOI 10.1200/jco.18.01295↗
- Paper Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After P… DOI 10.1001/jamaoncol.2016.5383↗
- Howard S. Höchster · 2 shared papers, 2017–2019 · strength 0.14
- Paper Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Pa… DOI 10.1200/jco.18.01295↗
- Paper Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After P… DOI 10.1001/jamaoncol.2016.5383↗
- Andrew Eugene Hendifar · 2 shared papers, 2017–2018 · strength 0.12
- Paper HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Pat… DOI 10.1200/jco.2017.74.9564↗
- Paper Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After P… DOI 10.1001/jamaoncol.2016.5383↗
- Andrea Wang‐Gillam · 2 shared papers, 2017–2018 · strength 0.12
- Paper HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Pat… DOI 10.1200/jco.2017.74.9564↗
- Paper Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After P… DOI 10.1001/jamaoncol.2016.5383↗
- Ramesh K. Ramanathan · 1 shared paper, 2019 · strength 0.08
- Jill Lacy · 1 shared paper, 2019 · strength 0.08
- Anthony Frank Shields · 1 shared paper, 2019 · strength 0.08
- Elena Gabriela Chiorean · 1 shared paper, 2019 · strength 0.08
- Paul S. Ritch · 1 shared paper, 2018 · strength 0.06
- Andrea J. Bullock · 1 shared paper, 2018 · strength 0.06
- Darren S. Sigal · 1 shared paper, 2018 · strength 0.06
- Fadi Braiteh · 1 shared paper, 2018 · strength 0.06
- Mark M. Zalupski · 1 shared paper, 2018 · strength 0.06
- Lei Zheng · 1 shared paper, 2018 · strength 0.06
- Nathan Bahary · 1 shared paper, 2018 · strength 0.06
- Paul E. Oberstein · 1 shared paper, 2018 · strength 0.06
- Charles David Blanke · 1 shared paper, 2017 · strength 0.06
- Dana Backlund Cardin · 1 shared paper, 2017 · strength 0.06
- Andrew M. Lowy · 1 shared paper, 2017 · strength 0.06
- Vincent M. Chung · 1 shared paper, 2017 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.